Bottom line
PBE vs RYOIX: the short answer
PBE (Invesco Biotechnology & Genome ETF) and RYOIX (Biotechnology Fund) are quite different portfolios: only about 37% of their top holdings (by weight) are shared.
But RYOIX is far broader, holding 74 positions to 33 for PBE, so beyond the top names it adds exposure PBE doesn't have.
PBE is cheaper at 0.59% vs 1.38% — a difference of $79 a year per $10,000 invested.
Over five years, RYOIX returned +4.0% a year vs +3.4% for PBE.
Updated Nov 19, 2026
PBE vs RYOIX side by side
| PBE | RYOIX | |
|---|---|---|
| Type | ETF | Mutual fund |
| Fund family | Invesco | Guggenheim |
| Category | Technology Sector | Technology Sector |
| Expense ratio | 0.59% | 1.38% |
| Annual cost per $10k | $59 | $138 |
| 10-yr cost on $10k (prospectus) | $738 | $1,709 |
| Max front load | None | — |
| 12b-1 fee | — | 0% |
| 1-yr return | +24.7% | +30.7% |
| 5-yr return (annualized) | +3.4% | +4.0% |
| 10-yr return (annualized) | +5.2% | +5.9% |
| Best quarter | +25.3% | +28.3% |
| Worst quarter | −24.3% | −22.5% |
| Net assets (fund) | $281.9M | $136.8M |
| Number of holdings | 33 | 74 |
| Portfolio turnover | 103% | 75% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | PBE | RYOIX | Difference |
|---|---|---|---|
| 2025 | +24.7% | +30.7% | −6.0% |
| 2024 | +1.1% | −0.7% | +1.8% |
| 2023 | +3.7% | +6.1% | −2.4% |
| 2022 | −10.8% | −13.1% | +2.3% |
| 2021 | +1.6% | +1.8% | −0.2% |
| 2020 | +25.5% | +22.1% | +3.4% |
| 2019 | +18.3% | +25.0% | −6.8% |
| 2018 | +0.2% | −9.0% | +9.2% |
| 2017 | +22.4% | +29.7% | −7.3% |
| 2016 | −23.0% | −19.5% | −3.5% |
Source: Fund prospectus bar charts
Holdings overlap
10 of PBE's top 25 holdings also appear in RYOIX's top 25.
| Holding | PBE | RYOIX |
|---|---|---|
| Regeneron Pharmaceuticals, Inc. | 5.47% | 2.93% |
| Amgen Inc. | 5.22% | 5.05% |
| Vertex Pharmaceuticals Inc. | 4.99% | 4.32% |
| Biogen Inc. | 4.79% | 2.13% |
| Gilead Sciences, Inc. | 4.43% | 4.49% |
| United Therapeutics Corp. | 4.08% | 1.72% |
| Illumina, Inc. | 3.51% | 1.94% |
| Alnylam Pharmaceuticals, Inc. | 3.17% | 2.36% |
| Incyte Corp. | 3.06% | 1.62% |
| Neurocrine Biosciences, Inc. | 2.66% | 1.52% |
Source: SEC Form N-PORT
PBE top 10
- Invesco Private Prime Fund — 12.89%
- Regeneron Pharmaceuticals, Inc. — 5.47%
- Amgen Inc. — 5.22%
- CareDx, Inc. — 5.04%
- Vertex Pharmaceuticals Inc. — 4.99%
- Invesco Private Government Fund — 4.97%
- Royalty Pharma PLC — 4.94%
- Biogen Inc. — 4.79%
- Gilead Sciences, Inc. — 4.43%
- United Therapeutics Corp. — 4.08%
RYOIX top 10
- Abbvie Inc — 8.17%
- Amgen Inc — 5.05%
- Gilead Sciences Inc — 4.49%
- Vertex Pharmaceuticals Inc — 4.32%
- Regeneron Pharmaceuticals Inc — 2.93%
- Revolution Medicines Inc — 2.48%
- Alnylam Pharmaceuticals Inc — 2.36%
- Beone Medicines Ltd — 2.17%
- Moderna Inc — 2.15%
- Biogen Inc — 2.13%
FAQ
What is the difference between PBE and RYOIX?
Which is cheaper, PBE or RYOIX?
Should I own both PBE and RYOIX?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.